Posts

November 17, 2026 Measles Is No Longer a Visitor What losing our elimination status means, who it affects, and what each of us can do (this is a long article, but is divided into sections). Today, the Pan American Health Organization made official what many of us in public health had been bracing for. The United States has lost its measles elimination status. We held it for 26 years. I was Maine’s state health officer in 2000, the year the country earned it. A decade earlier, I was a young pediatric resident physician in Los Angeles, vaccinating children in an inner-city McDonald’s while a measles epidemic kept our hospital overflowing. I did not expect to see that story start over. What we actually lost Elimination never meant zero cases. It meant measles came here only as a visitor. A traveler would bring it in, it would find a pocket of unvaccinated people, public health workers would surround it, and within weeks or months the chain would die out. Losing the status means the chains are no longer dying out. The same virus has been passing from person to person inside this country for more than a year. Measles is not visiting anymore. It lives here. The numbers tell the same story. The U.S. has confirmed more than 5,400 cases so far this year, more than double last year’s total and the most since 1991. That brings the total since the start of 2025 past 7,700. About 600 people have been hospitalized. State health departments have reported 10 deaths this year, at least five of them children. Two were reported on a single day, Nov. 13: a child in Wisconsin and an unvaccinated resident of Montour County, Pennsylvania. Almost everyone who has become ill was unvaccinated or had no record of vaccination. The designation itself carries no penalty. No law changed this week, no border closed, and no school rule was rewritten. I think of it as a diagnosis. A diagnosis does not make you sick. It names what is already true, and it tells you what needs treating. PAHO’s director, Dr. Jarbas Barbosa, said as much today: the loss means the virus has been circulating long enough to put families and communities at risk of a preventable illness. How the door opened This did not happen in one year. Before the pandemic, about 95 percent of American kindergartners were vaccinated against measles. Today it is about 92 percent, and 39 states have fallen below 95. That sounds like a small slip. It adds up to nearly 300,000 kindergartners without that protection. For a virus this contagious, it is the difference between a spark that dies and a fire that spreads. We are also victims of our own success. Before the vaccine, nearly every American child caught measles, and each year it put about 48,000 people in the hospital and killed 400 to 500. When a disease like that disappears, our memory of it goes too, and misinformation moves into the empty space. Even most clinicians practicing today have never seen a patient with measles. I have. What I have seen measles do Measles was a disease of the past when I was growing up in Maine in the 1960s and 70s. Early in my medical career, I learned otherwise. In the mid-to-late 1980s, while working in Tanzania, I watched children being carried into the hospital severely ill with measles. At that time, one in six hospital deaths there was due to measles, most of them young children. Most were unvaccinated, and not by choice. The vaccine must be kept cold, and families lived scattered across the countryside, far from reliable refrigeration. Months later I came home, relieved to be back in a country that seemed on the verge of ending measles. Then, as a resident physician at Children’s Hospital Los Angeles, I found myself in the middle of the largest U.S. outbreak since the 1960s. From 1988 to 1990, California reported more than 16,000 cases, nearly 3,400 hospitalizations, and 75 deaths. Most of the children who died were unvaccinated and lived in poor neighborhoods, surrounded by some of the most advanced medical centers in the world. The photos in the textbooks show the rash. They do not show how terribly sick these children are. The new measles The measles I met in Los Angeles was mostly a disease of young children. This time is different. About four in ten cases this year have been in adults. Dr. Paul Offit, the pediatrician and vaccine scientist at Children’s Hospital of Philadelphia, calls it “the new measles.” It is reaching pregnant women. In Pennsylvania alone, 97 pregnant women have had measles this year. Measles in pregnancy raises the risk of pneumonia, miscarriage, and early labor, and a mother who is sick near delivery can pass the virus to her baby. At least six Pennsylvania babies have been born with measles, something most of us in pediatrics have never seen, and Dr. Offit reports that one has died. Even babies who recover are not always safe. Years later, some develop SSPE, a brain disease that is always fatal. A California study put the risk at about 1 in 600 for babies who catch measles in their first year of life. What changes, and for whom If you are fully vaccinated, very little changes. Two doses of a measles-containing vaccine (e.g., MMR) since 1968 are about 97 percent effective, and the protection is long-lasting. The risk falls on those who cannot be vaccinated: babies under 12 months, pregnant women, and people whose immune systems are weakened by illness or treatment. They depend on the rest of us. If you have a baby, the advice has already shifted. The protection babies get from their mothers fades by about six months, and the routine first dose of MMR does not come until twelve. An early dose in between, often called a “zero dose,” fills that gap without replacing the regular two. The Maine CDC now recommends it for infants 6 to 11 months old who are traveling abroad, traveling to a part of the U.S. with an outbreak, or expecting close contact with non-immune visitors from places where measles is spreading. Two babies died of measles earlier this month, a 7-month-old in New York and an infant in Wisconsin. Former CDC director Dr. Rochelle Walensky and Benjamin Rader of Boston Children’s Hospital argued this week that national guidance should offer this dose far more widely, with nearly 2 million American infants in that window as holiday travel begins. With the holidays coming, that is worth checking on. If you are pregnant or hope to be, check your immunity before you conceive. The MMR vaccine cannot be given during pregnancy, so the time to get it is at least a month beforehand. If you are already pregnant and unsure of your immunity, ask the people around you to be vaccinated, and call your provider right away after any exposure. A treatment called immune globulin can help protect you and your baby if it is given within six days. If you care for patients, the question we were all trained to ask, “Have you traveled outside the country?”, no longer screens for measles. Fever and a rash now put measles on the list for any patient of any age. Ask patients to call ahead, mask and isolate them on arrival, test, and call your state health department right away. Ask about pregnancy, too. An exposed pregnant patient without evidence of immunity needs immune globulin within six days, and a newborn whose mother had measles near delivery needs urgent evaluation. Make sure your own immunity, and your team’s, is documented. If you are visiting the U.S., nothing changes at the border. But we are now the kind of destination we used to warn our own travelers about. If family or friends are coming from abroad, especially with a baby, encourage them to be fully vaccinated before they travel. For our neighbors, we have become an exporter. Mexico’s largest outbreak began with a child who caught measles while visiting family in Texas. Today Mexico and Bolivia lost their elimination status along with us. Canada lost its own a year ago and cannot regain it before late 2027. Measles is now endemic again in all three of North America’s largest countries, and every infection that crosses a border makes the road back harder for all of us. For public health, the road back is long. To regain elimination status, a country must show at least 12 straight months without continuous spread, with the data to prove it. Countries in our hemisphere that lost their status have needed more than two years after the spread stopped. PAHO’s director has said the return of measles to the Americas can be fully reversed, but only with decisive action. Federal health officials say their approach will stay the same. Many health leaders are asking for more, starting with a national vaccination campaign. Clear guidance makes a difference. After Michigan widened its early-dose recommendation around two county outbreaks, more than 2,300 babies got that dose in about six weeks, triple the number a year earlier. The view from Maine Maine is better protected than most. Ninety-eight percent of our kindergartners are vaccinated against measles, one of the highest rates in the nation. That reflects a law passed in 2019, upheld by Maine voters in 2020 (with ~73% of voters supporting), and in effect since 2021, which allows only medical exemptions for vaccines required for school. We have had six cases this year. Five began with one traveler in Penobscot County in February, and a sixth was confirmed in Somerset County in September. Our public health teams contained them. But a statewide average hides the gaps. There are babies too young for the vaccine, adults unsure of their own records, and communities where rates run lower. Measles is contagious enough to find them. The virus can hang in the air of a room for two hours after an infected person has left. What each of us can do Check your own immunity. You are considered protected if you have a record of two doses of measles vaccine given since 1968, a documented history of measles, or a birth date before 1957. Not sure? Your primary care provider can help find your records, order a blood test, or simply give you an MMR. That last option is often the easiest. With so many cases now in adults, this step is for grown-ups as much as for children. The vaccine is not given during pregnancy or to people who are immunocompromised, which is one more reason for the rest of us to get it. Protect the babies in your life. Make sure the adults and older children around an infant are vaccinated, and ask the pediatrician about an early dose before travel or holiday visits. Call before you walk in. If you or your child has a fever and a rash, phone the office or emergency department first, so they can keep you out of a crowded waiting room. Be someone people can ask. In Pennsylvania’s Amish country, the center of the nation’s largest outbreak, nurses have vaccinated more than 6,000 people in kitchens, barns, and fire halls, in the evening after chores. Nobody there is compromising on the science. They are compromising on everything else: the place, the hour, the pace, the tone. One community leader’s advice was to encourage, not push. I learned the same thing in that Los Angeles McDonald’s. Most parents who hesitate are not opponents. They are parents with questions, and they deserve a patient answer from someone they trust. Stand up for the unglamorous work. School nurses, disease investigators, public health labs, and vaccine clinics are the reason one case stays one case. They need steady funding and our support. We have done this before Here is what gives me hope. The epidemic I worked through as a resident sickened more than 55,000 Americans and killed 123 between 1989 and 1991. The country responded. We added a second dose of vaccine for every child. We created the Vaccines for Children program so that cost would not keep any child from a vaccine. We took vaccines to where families were. By 2000, measles was eliminated. In 2024, I returned to the Tanzanian village where I worked in the 1980s. Measles has become much rarer there. Over the years, Tanzania added refrigeration, including mobile units, and built yearly campaigns that carry trusted information and the vaccine out to every community. If a rural village can push measles back with a portable refrigerator and a plan, so can we. Measles moved back in because we left the door open. We know how to close it. I have watched it done twice.Measles Is No Longer a Visitor

  Measles Is No Longer a Visitor The View from Maine: What losing our elimination status means, who it affects, and what each of us can do DORA ANNE MILLS November 17, 2026 Measles Is No Longer a Visitor   Today, the Pan American Health Organization made official what many of us in public health had been bracing for. The United States has lost its measles elimination status. We held it for 26 years. I was Maine’s state health officer in 2000, the year the country earned it. A decade earlier, I was a young pediatric resident physician in Los Angeles, vaccinating children in an inner-city McDonald’s while a measles epidemic kept our hospital overflowing. I did not expect to see that story start over. What we actually lost Elimination never meant zero cases. It meant measles came here only as a visitor. A traveler would bring it in, it would find a pocket of unvaccinated people, public health workers would surround it, and within weeks or months the chain would die out. Losing th...

Senate bill gives NIH a $500 million raise in 2027

 Science  Senate bill gives NIH a $500 million raise in 2027 Research advocates pleased by 1% increase to $49 billion, but urge Congress to block rule imposing politics on grantmaking 17 NOV 2026  2:55 PM ET BY JOCELYN KAISER The U.S. National Institutes of Health (NIH) would get a $500 million raise to $49 billion in fiscal year 2027 in a spending bill  released  last night by a Senate spending panel. That modest 1% raise is $400 million more than contained in a House of Representatives bill and pushes back on President Donald Trump’s proposed 12% cut to the agency. The bill does not include provisions in the House measure,  released  in June, that called for restricting certain research areas and drew concerns from the biomedical research community. But advocates are disappointed the Senate measure would not specifically stop the White House from moving ahead with a proposed rule that would politicize federal grantmaking. The NIH funding is included ...

New US Congress should ‘reimagine’ science — not just return to the past

 Nature News New US Congress should ‘reimagine’ science — not just return to the past For science policy to be effective, the public must be engaged in the process of funding research. by Kenneth M. Evans The US Democratic Party’s sweeping victory, which saw the party take electoral majorities in both chambers of the US Congress, has rekindled optimism in the science community over the future of the nation’s research system. Science advocacy organizations and members of Congress are now rushing to address scientists’ most pressing question: how much money will be allocated to research in the spending bill for the fiscal year 2027? When it convenes on 3 January, the 120th Congress should also address two thornier, longer-term questions: who should get to participate in making decisions about science and technology? And how can policy institutions adapt to include more public voices? These questions sit at the centre of science’s ‘social contract’, the government-led support system t...

US Supreme Court rebuffs White House effort to cut research grants

Nature News US Supreme Court rebuffs White House effort to cut research grants The high court has declined for now to intervene in a key case, meaning that lower court rulings that restored several hundred terminated grants will stand. By   Max Kozlov  &  Dan Garisto The US Supreme Court has dealt a blow to the Trump administration’s efforts to  terminate research grants it deemed at odds with its political priorities . The court said today that  it would, for now, not intervene in a landmark legal battle over the cancellation of research grants  by the US National Science Foundation (NSF) and four other federal agencies. The court’s decision leaves in place several lower-court rulings that came out this year and last and required the reinstatement of hundreds of cancelled awards while a lawsuit brought by a group of scientists against the government proceeds. Since early 2025, US President Donald Trump’s administration has cancelled thousands of grants...

Researchers have a wish list. Can the new Congress deliver?

 Science Insider Researchers have a wish list. Can the new Congress deliver? Despite a healthy majority, Democrats face limits on what they can achieve 10 NOV 2026  3:35 PM ET BY JEFFREY MERVIS Last week’s U.S. midterm elections have  given Democrats large majorities  in both chambers of the new Congress that convenes in January 2027. Democratic lawmakers say they will aggressively investigate President Donald Trump’s economic policies, the Iran war, and other steps his administration has taken since taking office in 2025. But it’s not clear whether efforts to blunt Trump’s moves to remake U.S. science will be a major part of that agenda. Here’s a look at what many researchers want from the 120th Congress at a time when it has many other issues to tackle, Trump still wields the veto pen, and federal judges could have the final say. We’ve rated their chances of success on a sliding scale, on which no wish is either certain or absolutely out of the question. LIMIT POLI...

This week's community morning yoga express - Tuesday and Thursday

 Join me in the Scarborough main conference room on this week or on zoom - Tuesday 17th and Thursday 19th: 8:00am-8:30am https://maine.zoom.us/j/4625543963 If you are joining in person in the main conf room in Scarborough, mats are available in the lobby closet. Come early to make yourself a space for practice.

Why does therapeutic drug development take so long? Treating pain without risk of addiction: Suzetrigine

Image
 Science Fight Club Why does therapeutic drug development take so long? Treating pain without risk of addiction: Suzetrigine By Jeremy M. Berg, PhD, Stand Up for Science Advisor The final case of this series involves a drug that was only recently developed and approved. It seems to be a major breakthrough, but it is too early to tell if it will be a commercial and cultural success. Aspirin and COX-2 inhibitors like NSAIDs are useful for treating some kinds of pain. However, for more severe pain, other drugs are needed and used. Many of these are based on opium, a preparation from certain poppies that humans have used for more than 8,000 years, as it induces euphoria in addition to decreasing pain. The most important compound in opium is morphine, a remarkably potent pain killer that binds to receptors in the brain that normally respond to specific peptides in the brain called enkephalins, b-endorphin, and dynorphins. Morphine and related natural and synthetic compounds that ac...